Skip to Main Content

Author Details

Piet Ost
Ghent University, GZA Ziekenhuizen
2002
273
49
PMIDPaper TitleJournal TitlePublished Year
37599133Docetaxel Provides Oncological Benefits in the Era of New-Generation Androgen Receptor Inhibitors - or Is Three a Crowd?Clin Genitourin Cancer2024
37945451The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies.Eur Urol2024
37821242PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial.Eur Urol Oncol2024
36151031The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review.Eur Urol Focus2023
37945903Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants.Nat Genet2023
38047214Elective Nodal Irradiation for Oligorecurrent Nodal Prostate Cancer: Interobserver Variability in the PEACE V-STORM Randomized Phase 2 Trial.Adv Radiat Oncol2023
37827280Microbiome and metabolome dynamics during radiotherapy for prostate cancer.Radiother Oncol2023
37725131Stereotactic body radiation therapy after radical prostatectomy: current status and future directions.World J Urol2023
37809056A geometry and dose-volume based performance monitoring of artificial intelligence models in radiotherapy treatment planning for prostate cancer.Phys Imaging Radiat Oncol2023
37292496<i>AR</i> and <i>PI3K</i> Genomic Profiling of Cell-free DNA Can Identify Poor Responders to Lutetium-177-PSMA Among Patients with Metastatic Castration-resistant Prostate Cancer.Eur Urol Open Sci2023
37352385Whole Slide Imaging-Based Prediction of TP53 Mutations Identifies an Aggressive Disease Phenotype in Prostate Cancer.Cancer Res2023
37217391Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty.Eur Urol2023
37016933Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study.Technol Cancer Res Treat2023
37410476Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.JAMA Oncol2023
37173210Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer.Eur Urol2023
37170654Accuracy and reliability of a commercial treatment planning system in nontarget regions in modern prostate radiotherapy.J Appl Clin Med Phys2023
37003085Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.Eur J Cancer2023
37164128Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.Ann Oncol2023
37030077Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer.Eur J Cancer2023
36925317Experiences of Men With Prostate Cancer Participating in a Clinical Pathway With a Supervised Group-based Exercise Program to Combat Androgen Deprivation-Induced Side Effects: A Qualitative Focus Group Study.Semin Oncol Nurs2023
36858728Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium.Lancet Oncol2023
36404204Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer.Eur Urol2023
36473945Using PSMA imaging for prognostication in localized and advanced prostate cancer.Nat Rev Urol2023
36708787WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer.Int J Radiat Oncol Biol Phys2023
36633862The MIRAGE Trial-Optical Illusion or the Future of Prostate Stereotactic Radiotherapy?JAMA Oncol2023
36494221Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.Eur Urol2023
36154809Evaluating the Impact of Prostate Only Versus Pelvic Radiotherapy for Pathological Node-positive Prostate Cancer: First Results from the Multicenter Phase 3 PROPER Trial.Eur Urol Focus2023
36283936Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers.Eur Urol Oncol2023
34289231Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study).BJU Int2022
35680076Health related quality of life outcomes following stereotactic body radiotherapy in patients with oligo-metastatic disease: A systematic review and individual patient data meta-analysis.Radiother Oncol2022
35411446Impact of <sup>18</sup>F-PSMA-11 PET/CT on Management of Biochemical Recurrence and High-Risk Prostate Cancer Staging : <sup>18</sup>F-PSMA-11 PET/CT and Impact on Prostate Cancer Management.Mol Imaging Biol2022
35476942Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial.Radiother Oncol2022
35507889Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer.JCO Precis Oncol2022
35440417Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11].Eur Urol2022
35494057Survival Outcomes and Pattern of Relapse After SABR for Oligometastatic Prostate Cancer.Front Oncol2022
35860387Epidemiology of spinal metastases, metastatic epidural spinal cord compression and pathologic vertebral compression fractures in patients with solid tumors: A systematic review.J Bone Oncol2022
35690515<sup>18</sup>F-PSMA-11 Versus <sup>68</sup>Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial.Eur Urol2022
35450732Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.Eur Urol2022
35657158Genomic biomarkers to guide precision radiotherapy in prostate cancer.Prostate2022
36001857Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.J Clin Oncol2022
36244387Stereotactic Body Radiation Therapy for Oligometastasis: GUst Do It?Int J Radiat Oncol Biol Phys2022
36228761Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus.Radiother Oncol2022
36192243A systematic review and meta-analysis on non-metastatic castration resistant prostate cancer: The radiation oncologist's perspective.Semin Oncol2022
35257847Impact of radiotherapy parameters on the risk of lymphopenia in urological tumors: A systematic review of the literature.Radiother Oncol2022
35317973Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate Cancer.Eur Urol Focus2022
35013522Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics.Prostate Cancer Prostatic Dis2022
35248825New targets, new hopes.ESMO Open2022
35152271Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score.Prostate Cancer Prostatic Dis2022
35090339Bone health and therapeutic agents in advanced prostate cancer.Front Biosci (Landmark Ed)2022
35063309Stereotactic Ablative Radiotherapy as a Tool in Renal Cell Carcinoma for Building RAPPORT with Systemic Therapy.Eur Urol2022
  • 1 - 50 of 273

Recommended Authors

Robert T Dess
University of Michigan ann arbor
Career Start Year 2016
Number of shared co-authors 41
Jesus E Juarez
University of California Los Angeles
Career Start Year 2015
Number of shared co-authors 29
Soumyajit Roy
Rush University Medical Center
Career Start Year 2013
Number of shared co-authors 17
R Jeffrey Karnes
Mayo Clinic
Career Start Year 2013
Number of shared co-authors 36
William C Jackson
University of Michigan ann arbor
Career Start Year 2013
Number of shared co-authors 37
Kiri A Sandler
Oregon Health and Science University
Career Start Year 2012
Number of shared co-authors 19
Xin Pei
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 4
Ting Martin Ma
University of Washington
Career Start Year 2010
Number of shared co-authors 32
Jure Murgic
University Hospital Center Sestre Milosrdnice
Career Start Year 2008
Number of shared co-authors 16
Suneil Jain
Cancer Centre Belfast City Hospital, Queen's University Belfast
Career Start Year 2008
Number of shared co-authors 31
Arun A Azad
Peter MacCallum Cancer Centre
Career Start Year 2007
Number of shared co-authors 24
Rahul D Tendulkar
Taussig Cancer Institute, Cleveland Clinic
Career Start Year 2006
Number of shared co-authors 32
Scott T Tagawa
Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital
Career Start Year 2003
Number of shared co-authors 35
Zhigang Zhang
Memorial Sloan Kettering Cancer Center
Career Start Year 2001
Number of shared co-authors 11
Chandana A Reddy
Cleveland Clinic
Career Start Year 2000
Number of shared co-authors 32
Wolfgang Lilleby
Oslo University Hospital
Career Start Year 1999
Number of shared co-authors 28
Daniel J Krauss
William Beaumont School of Medicine
Career Start Year 1999
Number of shared co-authors 27
Robert B Den
Thomas Jefferson University Hospital
Career Start Year 1999
Number of shared co-authors 57
Mark K Buyyounouski
Stanford University
Career Start Year 1999
Number of shared co-authors 25
Simeng Suy
MedStar Georgetown University Hospital
Career Start Year 1996
Number of shared co-authors 16
Eric M Horwitz
Fox Chase Cancer Center
Career Start Year 1996
Number of shared co-authors 43
Jonathan D Tward
Huntsman Cancer Institute, University of Utah
Career Start Year 1994
Number of shared co-authors 34
Glenn Bauman
Western University and London Regional Cancer Program
Career Start Year 1994
Number of shared co-authors 8
William Robert Lee
Duke University School of Medicine
Career Start Year 1993
Number of shared co-authors 27
Thomas M Pisansky
Mayo Clinic
Career Start Year 1992
Number of shared co-authors 43
Richard Choo
Mayo Clinic
Career Start Year 1991
Number of shared co-authors 25
Jeff M Michalski
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 39
Christopher R King
University of California los angeles
Career Start Year 1988
Number of shared co-authors 23
Anthony V D'Amico
Duke University Medical Center
Career Start Year 1988
Number of shared co-authors 61
Howard M Sandler
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Career Start Year 1976
Number of shared co-authors 62

Collaborators

Gert De Meerleer
University Hospitals Leuven
Co-authored papers 81
Alberto Briganti
IRCCS San Raffaele Scientific Institute
Co-authored papers 40
Roderick C N van den Bergh
St. Antonius Hospital
Co-authored papers 21
Giorgio Gandaglia
IRCCS San Raffaele Scientific Institute, Italy Vita-Salute San Raffaele University
Co-authored papers 20
Derya Tilki
Universitatsklinikum Hamburg-Eppendorf
Co-authored papers 19
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 15
Phuoc T Tran
University of Maryland School of Medicine
Co-authored papers 15
Henrik Gr??nberg
Karolinska Institute
Co-authored papers 14
Inge M van Oort
Radboud University Medical Center
Co-authored papers 11
Almudena Zapatero
University Hospital La Princesa
Co-authored papers 10
Gerhardt Attard
The Institute of Cancer Research
Co-authored papers 9
Declan G Murphy
Peter MacCallum Cancer Centre, University of Melbourne
Co-authored papers 9
Catharine M L West
University of Manchester
Co-authored papers 9
Matthew P Deek
Rutgers Robert Wood Johnson Medical School, Rutgers University
Co-authored papers 8
Robert Jeffrey Karnes
Mayo Clinic
Co-authored papers 8
Alison M Dunning
Co-authored papers 8
Johann S de Bono
The Institute for Cancer Research
Co-authored papers 8
Rosalind A Eeles
The Institute of Cancer Research
Co-authored papers 8
Hendrik Van Poppel
University Hospitals Leuven
Co-authored papers 8
Janet L Stanford
Fred Hutchinson Cancer Research Center
Co-authored papers 7
Johan Lindberg
Karolinska Institute
Co-authored papers 7
Fred Saad
University of Montreal Health Center
Co-authored papers 7
Børge G Nordestgaard
Co-authored papers 7
Demetrius Albanes
Co-authored papers 7
Christopher A Haiman
University of Southern California
Co-authored papers 7
David E Neal
University of Oxford, John Radcliffe Hospital
Co-authored papers 7
Kathryn L Penney
Co-authored papers 7
Emmanuel S Antonarakis
The Sidney Kimmel Cancer Comprehensive Cancer Center at Johns Hopkins
Co-authored papers 7
Zsofia Kote-Jarai
The Institute of Cancer Research
Co-authored papers 7
Cezary Cybulski
International Hereditary Cancer Center, Pomeranian Medical University
Co-authored papers 7
Release 1.2